A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma

Inclusion Criteria Concurrent Medication: Allowed: * Ongoing and/or maintenance therapy for opportunistic infection. * Medications for nausea, vomiting, and diarrhea resulting from drug. Patients must have AIDS related Kaposi's sarcoma. * Patients may demonstrate positive blood cultures for Mycobacterium avium-complex or cytomegalovirus. Exclusion Criteria Co-existing Condition: Patients with the following conditions will be excluded: * Patients with active opportunistic infection. * Patients with concurrent neoplasm other than squamous cell carcinoma of the skin or in situ carcinoma of the cervix. * Patients with significant neurologic, cardiac, or liver disease. Concurrent Medication: Excluded: * Antiretroviral agents. * Immunomodulators. * Corticosteroids. * Experimental drugs. The following patients will be excluded from the study: * Patients with lymphadenopathy alone and/or visceral disease alone secondary to Kaposi's sarcoma. Prior Medication: Excluded: * Cytotoxic chemotherapy. * Excluded within 30 days of study entry: * Antiretroviral agents. * Biologic modifiers. * Corticosteroids. Prior Treatment: Excluded: * Total body electron beam therapy. * Excluded within 30 days of study entry: * Radiation therapy.